What records are connected here?
- Evidence lanes
- 3
- Source years
- 12
- Drugs@FDA applications
- 6
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsInfections
Dalbavancin is a lipoglycopeptide antibiotic, a member of the glycopeptide family, and the active ingredient in Dalvance.1,2 FDA approved Dalvance in 2014 for acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).1,2 Two randomized, double-blind trials in 1,312 adults compared it with vancomycin. The label has no boxed warning but warns of serious allergic reactions.1
| What it is | A lipoglycopeptide antibacterial made from a fermentation product of Nonomuraea bacteria, consisting of five closely related active forms, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Dalvance, NDA 021883, with an original approval date of May 23, 2014. The label has no boxed warning.1,2 |
| Human evidence | Two phase 3 randomized, double-blind trials in 1,312 adults with skin infections, and a third comparing two treatment plans, described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Dalbavancin is a lipoglycopeptide antibacterial synthesized from a fermentation product of Nonomuraea bacteria. The label states that it is a mixture of five closely related active forms that share a core structure and differ in a fatty-acid side chain.1
In the United States it is the active ingredient of Dalvance, approved under NDA 021883, according to Drugs@FDA.2
It is an antibacterial drug active against Gram-positive bacteria such as Staphylococcus aureus, including methicillin-resistant strains, and several streptococci, according to the label.1
The label states that its antibacterial activity in animal infection models correlates best with the ratio of drug exposure over time to the minimum concentration that inhibits the bacteria.1
Trials 1 and 2 randomly assigned 1,312 adults with acute bacterial skin infections, such as cellulitis, major abscesses and wound infections, to dalbavancin or vancomycin, with an option to switch to linezolid, according to the label.1
Clinical success at day 26 to 30 was 83.7% with dalbavancin and 88.1% with the comparator in Trial 1, and 88.1% and 84.5% in Trial 2, in the intent-to-treat population. A third trial in 698 patients compared two treatment plans of dalbavancin with similar results.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Dalvance, NDA 021883, with an original approval date of May 23, 2014.2
The Dalvance label cited here (DailyMed SPL version 29, published November 17, 2025) states that it is indicated for adult and pediatric patients with acute bacterial skin and skin structure infections caused by designated susceptible Gram-positive bacteria.1
The label has no boxed warning. It warns of serious allergic and skin reactions, reactions during rapid infusion and raised liver enzymes, and advises care in people allergic to other glycopeptides.1
Its effectiveness for infections outside the skin, which its approved indication does not cover.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Dalbavancin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Dalbavancin are a bounded selection, not every registration or paper about Dalbavancin. For the years before Dalbavancin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Dalbavancin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Dalbavancin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Dalvance for acute bacterial skin infections. Approval rests on two randomized, double-blind trials in 1,312 adults comparing it with vancomycin. The label has no boxed warning.↗↗
Status sources checked through November 16, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Dalvance for acute bacterial skin infections. Approval rests on two randomized, double-blind trials in 1,312 adults comparing it with vancomycin. The label has no boxed warning.↗↗
The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date October 10, 2026
Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.↗Added to PeptideScanner November 16, 2026Regulatory · added November 17, 2026
Federal Register notice 2026-15149↗Source date July 28, 2026Regulatory · added November 17, 2026
Drugs@FDA application ANDA219604↗Source date June 4, 2026Regulatory · added November 17, 2026
Drugs@FDA application ANDA218602↗Source date February 26, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
10 of 11 selected trial records include at least one phase value; 11 of 11 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span October 12, 2009 to October 10, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 34931283 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2021-12-21 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06810583 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Literature metadata
PubMed lists PMID 41892415 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-03-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05046860 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-06-22, and PeptideScanner's reviewed identity mapping was dalbavancin.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients.↗
Literature metadata
PubMed lists PMID 40993014 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Systematic Review, Journal Article, with publication-date metadata of 2025-09-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.↗
Literature metadata
PubMed lists PMID 32603683 in International journal of antimicrobial agents as Journal Article, Systematic Review, with publication-date metadata of 2020-06-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 32629114 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-03 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 36808371 in European review for medical and pharmacological sciences as Review, Journal Article, with publication-date metadata of 2023-02 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026